Skip to content

CONTRIBUTORS

Evan McCulloch, CFA

Portfolio Manager, Research Analyst
Franklin Equity Group
United States

Key takeaways

  • China’s strategic focus on biotech has resulted in research and development (R&D) investments and other policies that have helped build the infrastructure (labs, talent pipelines, and capital) for the sector to scale rapidly.
  • Biotech companies in China are advancing pipelines that include dozens, sometimes hundreds, of drug candidates through Phase 2 trials, then out-licensing them for late-stage development.
  • If the United States wants to maintain leadership in biotechnology, it must follow China’s example in supporting innovation, speed and efficiency.
     

Setting the stage

When I first visited China nearly two decades ago, the country’s pharmaceutical sector was in a very different place. It was small in scale, focused almost entirely on the domestic market, and dominated by generic drugs or medicines in-licensed from Western companies. Local firms had limited research capabilities, and global biotech investors barely considered China a serious player.

Fast forward to 2025, and the transformation is staggering. Biotechnology has become one of Beijing’s top strategic priorities, supported by major government initiatives like “Made in China 2025” and the “14th Five-Year Bioeconomy Plan.”

“Made in China 2025” was a sweeping industrial policy launched to reduce the country’s dependence on foreign technology and elevate domestic innovation. For biotech, this meant direct investment into R&D, generous tax incentives, subsidies for drug development, and the creation of high-tech industrial parks dedicated to life sciences. The policy helped lay the infrastructure (labs, talent pipelines, and capital) for China’s biotech sector to scale rapidly.

“The 14th Five-Year Bioeconomy Plan” built on that foundation by making biotech one of the “pillar industries” for national growth. It called for accelerated development in precision medicine, novel therapies, and next-generation manufacturing. It also encouraged faster regulatory approval timelines, improved intellectual property protections, and policies to attract and retain top global scientific talent.

Together, these programs have fueled an innovation ecosystem unlike anything China has ever seen—one that is reshaping the global competitive landscape.

This year, I traveled to Shanghai and met with more than 50 public and private biotechnology companies. As I explain this paper, what I found was an industry brimming with ambition, scale and speed, along with important implications for US and European biotech companies.

A market growing up

On the flight home from Shanghai, one thought kept coming back: Chinese biotech is growing up fast. The country now has a powerful R&D engine, an efficient clinical trial ecosystem, and a pipeline of molecules that matter for global health.

This certainly raises the level of competition in global biotech, but that competition can make the whole industry stronger. I expect investors to increasingly favor companies pursuing truly novel science, while leaving incremental “me-too” approaches behind, especially as Chinese firms can develop those cheaper and faster.

For patients, this means the potential for bigger breakthroughs. For investors, it means a market full of both risks and opportunities. And for policymakers, it is a wake-up call: if the United States wants to maintain leadership in biotechnology, it must follow China’s example in supporting innovation, speed and efficiency.

WHAT ARE THE RISKS?

All investments involve risks, including possible loss of principal.

Equity securities are subject to price fluctuation and possible loss of principal.

Small- and mid-cap stocks involve greater risks and volatility than large-cap stocks.

Investment strategies which incorporate the identification of thematic investment opportunities, and their performance, may be negatively impacted if the investment manager does not correctly identify such opportunities or if the theme develops in an unexpected manner. Focusing investments in the health care, information technology (IT) and/or technology-related industries carries much greater risks of adverse developments and price movements in such industries than a strategy that invests in a wider variety of industries.

Any companies and/or case studies referenced herein are used solely for illustrative purposes; any investment may or may not be currently held by any portfolio advised by Franklin Templeton. The information provided is not a recommendation or individual investment advice for any particular security, strategy, or investment product and is not an indication of the trading intent of any Franklin Templeton managed portfolio.

WF: 6986459

Copyright ©2025. Franklin Templeton. All rights reserved.

This document is intended to be of general interest only. This document should not be construed as individual investment advice or offer or solicitation to buy, sell or hold any shares of fund. The information provided for any individual security mentioned is not a sufficient basis upon which to make an investment decision. Investments involves risks. Value of investments may go up as well as down and past performance is not an indicator or a guarantee of future performance. The investment returns are calculated on NAV to NAV basis, taking into account of reinvestments and capital gain or loss. The investment returns are denominated in stated currency, which may be a foreign currency other than USD and HKD (“other foreign currency”). US/HK dollar-based investors are therefore exposed to fluctuations in the US/HK dollar / other foreign currency exchange rate. Please refer to the offering documents for further details, including the risk factors.

The data, comments, opinions, estimates and other information contained herein may be subject to change without notice. There is no guarantee that an investment product will meet its objective and any forecasts expressed will be realized. Performance may also be affected by currency fluctuations. Reduced liquidity may have a negative impact on the price of the assets. Currency fluctuations may affect the value of overseas investments. Where an investment product invests in emerging markets, the risks can be greater than in developed markets. Where an investment product invests in derivative instruments, this entails specific risks that may increase the risk profile of the investment product. Where an investment product invests in a specific sector or geographical area, the returns may be more volatile than a more diversified investment product. Franklin Templeton accepts no liability whatsoever for any direct or indirect consequential loss arising from use of this document or any comment, opinion or estimate herein. This document may not be reproduced, distributed or published without prior written permission from Franklin Templeton.

Any share class with “(Hedged)” in its name will attempt to hedge the currency risk between the base currency of the Fund and the currency of the share class, although there can be no guarantee that it will be successful in doing so. In some cases, investors may be subject to additional risks.

Please contact your financial advisor if you are in doubt of any information contained herein.

For UCITS funds only: In addition, a summary of investor rights is available from here. The fund(s)/ sub-fund(s) are notified for marketing in various regions under the UCITS Directive. The fund(s)/ sub-fund(s) can terminate such notifications for any share class and/or sub-fund at any time by using the process contained in Article 93a of the UCITS Directive.

For AIFMD funds only: In addition, a summary of investor rights is available from here. The fund(s)/ sub-fund(s) are notified for marketing in various regions under the AIFMD Directive. The fund(s)/ sub-fund(s) can terminate such notifications for any share class and/or sub-fund at any time by using the process contained in Article 32a of the AIFMD Directive.

For the avoidance of doubt, if you make a decision to invest, you will be buying units/shares in the fund(s)/ sub-fund(s) and will not be investing directly in the underlying assets of the fund(s)/ sub-fund(s).

This document is issued by Franklin Templeton Investments (Asia) Limited and has not been reviewed by the Securities and Futures Commission of Hong Kong.

Unless stated otherwise, all information is as of the date stated above. Source: Franklin Templeton.

CFA® and Chartered Financial Analyst® are trademarks owned by CFA Institute.